Mirabegron Zentiva (Mirabegron)

Mirabegron works by selectively activating β3‑adrenergic receptors on the bladder’s detrusor smooth muscle. This activation triggers a cascade that relaxes the muscle during the storage phase, allowing the bladder to hold a larger volume of urine and decreasing the frequency of sudden urges to void.

The appropriate dose of Mirabegron Zentiva is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and any relevant clinical factors. The prescriber follows the product label and local regulatory guidance when selecting the dose.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details and any required import documentation.

Mirabegron belongs to the β3‑adrenergic agonist class, whereas antimuscarinics (e.g., oxybutynin, tolterodine) block muscarinic receptors. Mirabegron often has a lower incidence of dry mouth and constipation, common side effects of antimuscarinics, but may be associated with higher blood pressure. Choice of therapy depends on patient tolerance, comorbidities and physician judgment.

Mirabegron Zentiva tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources. Keep out of reach of children and dispose of any expired product according to local regulations.

Mirabegron Zentiva is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional and should not split, crush, or chew the tablet.

Serious risks include marked hypertension, tachycardia, severe urinary retention, angioedema, allergic reactions such as rash or anaphylaxis, and QT interval prolongation. Patients should seek immediate medical attention if they experience symptoms like a rapid or irregular heartbeat, significant blood pressure rise, swelling of the face or throat, or difficulty urinating.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any of the tablet’s excipients. Caution is also advised for individuals with a history of urinary retention or bladder outlet obstruction. Clinicians should review the patient’s medical history before initiating therapy.